113 Assessing predictors of NEDA in RRMS patients initiating dimethyl fumarate in a real-world setting. Issue 9 (12th August 2022)

• Record Type: Journal Article
• Authors: Al-Araji, Sarmad; Bianchi, Alessia; Eshaghi, Arman; Zhang, Le; Kanber, Baris; Jha, Ashwani; Goodkin, Olivia; Barkhof, Frederik; Nachev, Parashkev; Ciccarelli, Olga
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 93:Issue 9(2022)
• Page Start: e2
• Publication Date: 2022-08-12
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2022-abn2.157
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Introduction: No evidence of disease activity (NEDA) is a treatment goal when using disease modifying therapy for treating relapsing remitting multiple sclerosis (RRMS).1 However, predicting which patients may achieve NEDA is challenging. Objective: To identify the baseline clinical and MRI features that predict NEDA in patients initiating dimethyl fumarate (DMF). Method: In our observational study, we retrospectively collected clinical and radiological data acquired for patients with RRMS initiating DMF. Demographics and clinical details at MS onset and at DMF initiation (baseline) were evaluated. We investigated the associations between all the baseline clinical and MRI findings and NEDA at 24 months using a combined multiple logistic regression. Results: We had a total of 670 patients in our cohort and only 339 (50%) achieved NEDA at 24 months. Lower EDSS (Log odds[95%CI]= -0.19[-0.30 to -0.03], p=0.01), lower number of new MRI lesions at baseline (Log odds[95%CI]= -0.14[-0.32 to -0.04], p=0.01) and lower number of relapses in the previous 12 months (Log odds[95%CI]= -0.39[-0.77 to -0.26], p=0.0001) significantly predicted NEDA at 24 months. Conclusion: Significant predictors for achieving NEDA were the number of relapses in the previous year, the number of new MRI lesions and the EDSS at DMF initiation. This could be useful in clinical practice to counsel patients regarding their potential response to DMF.